SCHEMBL30153141

SCHEMBL30153141

COC(=O)c1ccc(O)c(C=O)c1

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 10/20 0.77
CA1 P00915 3/20 0.65
CA2 P00918 3/20 0.65
CA12 O43570 2/20 0.65
CA7 P43166 2/20 0.65
CA9 Q16790 2/20 0.65
CA14 Q9ULX7 2/20 0.65
XDH P47989 2/20 0.65
ALDH1A1 P00352 3/20 0.57
KDM4E B2RXH2 2/20 0.57
LMNA P02545 2/20 0.57
MEN1 O00255 1/20 0.57
TP53 P04637 1/20 0.57
MAPT P10636 1/20 0.57
HPGD P15428 1/20 0.57
ALOX15 P16050 1/20 0.57
ALOX12 P18054 1/20 0.57
HTT P42858 1/20 0.57
KMT2A Q03164 1/20 0.57
SMN1; SMN2 Q16637 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL310771 1.00 ERN1 (0.77) ERN1CA1CA2CA12CA7
SCHEMBL12767865 0.87 ERN1 (1.00) ERN1CA1CA2CA12CA7
SCHEMBL1485297 0.86 XDH (0.65) ERN1CA1CA2CA12CA7
SCHEMBL17747083 0.85 ALDH1A1 (0.58) ERN1CA1CA2CA12CA7
SCHEMBL5917939 0.84 CA1 (0.62) ERN1CA1CA2CA12CA7
SCHEMBL6640776 0.83 ERN1 (1.00) ERN1CA1CA2CA12CA9
SCHEMBL9125494 0.83 CA1 (0.61) ERN1CA1CA2CA12CA7
SCHEMBL9125499 0.83 CA1 (0.61) ERN1CA1CA2CA12CA7
SCHEMBL2316486 0.83 CA1 (0.61) ERN1CA1CA2CA12CA7
SCHEMBL3507686 0.82 ALDH1A1 (0.61) ERN1CA1CA2CA12CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4702026-A1 TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF Aeovian Pharmaceuticals, Inc. (US) 2026-03-04 EP disclosed
WO-2024226685-A1 TRICYCLIC FUSED IMIDAZOLE COMPOUNDS AS CD38 MODULATORS AND USES THEREOF AEOVIAN PHARMACEUTICALS, INC. (US) 2024-10-31 WO disclosed
EP-4441033-A1 NOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF Tango Therapeutics, Inc. (US) 2024-10-09 EP disclosed
EP-4359381-A1 CBL-B MODULATORS AND USES THEREOF Nimbus Clio, Inc. (US) 2024-05-01 EP disclosed
WO-2023102162-A1 TGONOVEL HDAC INHIBITORS AND THERAPEUTIC USE THEREOF TANGO THERAPEUTICS, INC. (US) 2023-06-08 WO disclosed
WO-2022272248-A1 CBL-B MODULATORS AND USES THEREOF NIMBUS CLIO, INC. (US) 2022-12-29 WO disclosed